Fierce Pharma
SEPTEMBER 15, 2024
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of chemotherapy. | Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate cancer with a combination free of chemotherapy.
MedCity News
SEPTEMBER 15, 2024
In the past, patient comfort often came at the cost of medical testing. However, the future of sleep monitoring doesn’t have to forgo either, with radar monitoring systems allowing for both a comfortable testing environment and a more accurate reading of sleep health. The post Redefining Sleep Health: From PSG Limitations to Next-Generation Solutions appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 15, 2024
Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona – showed that nearly two-thirds (61.6%) of patients with brain metastases at baseline who were treated with the HER2-directed antibody-drug conjugate (ADC) were alive without disease progression at one year.
MedCity News
SEPTEMBER 15, 2024
Roche’s Tecentriq Hybreza is a subcutaneously injectable formulation of the cancer drug Tecentriq while Ocrevus Zunovo is an injectable version of multiple sclerosis drug Ocrevus. Each is administered in minutes compared to an hour or more for infused therapies. The post Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs appeared first on MedCity News.
pharmaphorum
SEPTEMBER 15, 2024
GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class
MedCity News
SEPTEMBER 15, 2024
A new Mercer report predicts there will be a national surplus of about 30,000 nurses by 2028. Though an overall surplus is projected nationally, there will still be significant shortages of nursing labor in a handful of states, as well as most of the country’s rural areas. To solve this issue, providers need to recruit from wider labor pools, minimize nurses’ nonclinical tasks and prioritize creating a more supportive work environment.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 15, 2024
To realize true, sustainable savings in total cost of care, the healthcare system needs to reconsider the support — or lack of support — it provides throughout patients’ medication experiences and the snowball effect that creates on a lifetime of healthcare costs. The post Shifting Focus from Medication Costs to Medication Value appeared first on MedCity News.
Pharmaceutical Technology
SEPTEMBER 15, 2024
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
MedCity News
SEPTEMBER 15, 2024
Herself Health and Blue Cross and Blue Shield of Minnesota have shifted away from a fee-for-service arrangement to a value-based arrangement. The post Blue Cross and Blue Shield of Minnesota, Herself Health Shift To VBC Contract appeared first on MedCity News.
PharmaTech
SEPTEMBER 15, 2024
Webinar Date/Time: Fri, Sep 27, 2024 11:00 AM EDT
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmacy Times
SEPTEMBER 15, 2024
Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen.
Pharmacy Times
SEPTEMBER 15, 2024
Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.
Expert insights. Personalized for you.
218 
Let's personalize your content